An external safety review committee evaluated post-marketing events and found a confirmed safety signal of rare adverse events that may result in severe vision loss after Beovu use.
Novartis received reports of vasculitis in 14 patients treated for wet age-related macular degeneration with Beovu (brolucizumab-dbll) since its approval by the FDA in October 2019. The company initiated an internal review of the case reports and established an external safety review committee (SRC) to provide an independent review of the cases, according to a press release.
The SRC compared the reported (Read more...)
Uncategorized